• EMA cleared the Phase III trial of Alpha1H in non-muscle-invasive bladder cancer.
• TO5B warrant exercise runs July 20-31, 2026; about 5,400,000 warrants remain, implying potential proceeds of about SEK 32 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hamlet Biopharma AB published the original content used to generate this news brief on July 17, 2026, and is solely responsible for the information contained therein.